Shervin Pishevar Feels Big Tech is Too Big

Shervin Pishevar understands the technology industry. Uber and Virgin Hyperloop One represent only two significant tech endeavors Pisher contributed his talents. Don’t think he sees “all things tech” as good though.

The technology industry continues to be the bane of entrepreneur Shervin Pishevar. His complaints against the tech industry appear somewhat ironic. After all, he put so much time and effort into venture capital funding tech-oriented enterprises. Yet, he sees things as they are. Drawing from this experiences, he paints an accurate picture of the tech industry and its flaws. It doesn’t find the massive concentration of power in the big five tech company comforting. From his perspective, it makes sense that he stresses the importance of government oversight of technology ventures.

Shervin Pishevar also pushes the suggestion that the Justice Department utilize its antitrust powers to break up the top five tech corporations. Fans of Apple, Google, Facebook, Microsoft, and Amazon find themselves taken aback by the suggestion. They often remain enthralled at the tech companies and the products the companies produce.

However, end-user consumers aren’t usually involved business-wise with tech companies. A brilliant innovator launching a new app may wonder why there is pressure to constrict his/her growth in the market may have issues with the tech giants. Shervin Pishevar does note that tech success can exist outside the “Big Five” and Silicon Valley. Things may become easier if roadblocks were removed from the path of startups. Being forced to deal almost exclusively with five tech companies creates issues. What happens if you can’t get your app into the Apple store? Problems will ensue.

Ironically, Shervin Pishevar took his issues with tech companies public through Twitter. Pishevar went on a 21-hour tweet storm to discuss his troubles with the tech industry. Twitter won’t join the rankings of the five top companies any time soon though. Twitter’s fortunes don’t seem as bright.

https://www.imdb.com/name/nm6840912/

Sahm Adrangi Success Continues With Kerrisdale Capital

Kerrisdale Capital President and CEO Sahm Adrangi joined radio show Behind the Idea to discuss advanced techniques used to analyze proteostasis data. There was discussion about the climate for hedge funds.

Despite how bullish the market has been, and news stating that hedge funds are passe, stock analysis and selection is still on the table. At least, that’s how Kerrisdale sees it.

“We haven’t had a great deal of trouble picking long and short stocks or with fundamental investing,” says Adrangi.

Behind the Idea reviewed Kerrisdale Capital’s Proteostasis (PTI) Adrangi admits there is a bit of trouble with the thesis but it’s being worked on.

Sahm Adrangi has been a very integral part of Kerrisdale’s development. Since the company’s launch in 2009, there has been a vast increase in income. By 2017, the company’s net worth was $150 million. A hefty increase from the initial $1 million investment.

Recently, Sahm Adrangi has overseen significant changes within the hedge fund operations. He says the company will divert attention to more important and pressing functions such as biotechnology. Research is currently being published with Sage Therapeutics, Zagfen and others.

Sahm Adrangi is a man who has a lot on his plate. He has diverse talents and regularly attends conferences where he does what he does best — talk.

In the last year, he has spoken at such venues as Sohn Conference, Traders 4 a Cause, and Value Investing Conference. He has also appeared on national media outlets like Fox News, CNBC, and Bloomberg.

Adrangi holds a Bachelors of Arts degree from Yale University. Prior to his tenure at Kerrisdale, he worked for Longacre Fund Management LLC., Deutsche Bank and Chanin Capital Partners.

He is widely known for his expertise at short selling and publishing research on stocks. He is also a generous philanthropist.

https://endpts.com/kerrisdales-sahm-adrangi-leads-a-brutal-new-biotech-short-attack-as-trial-results-loom/